Holen Sie sich die Stockscreener-App
18.68
0.00%
-0.000719
Schlusskurs vom Vortag:
$18.68
Offen:
$18.73
24-Stunden-Volumen:
68,649
Relative Volume:
0.16
Marktkapitalisierung:
$946.56M
Einnahmen:
$62.02M
Nettoeinkommen (Verlust:
$-45.65M
KGV:
-20.31
EPS:
-0.92
Netto-Cashflow:
$-9.60M
1W Leistung:
-7.98%
1M Leistung:
+24.95%
6M Leistung:
+73.44%
1J Leistung:
+89.83%
1-Tages-Spanne:
$18.48
$18.85
1-Wochen-Bereich:
$18.39
$20.24
52-Wochen-Spanne:
$7.90
$20.33
Theravance Biopharma Inc Stock (TBPH) Company Profile
Firmenname
Theravance Biopharma Inc
Sektor
Branche
Telefon
650-808-6000
Adresse
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Vergleichen Sie TBPH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
18.68 | 947.57M | 62.02M | -45.65M | -9.60M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.49 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
720.28 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.21 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
898.86 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.53 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-03 | Eingeleitet | Oppenheimer | Outperform |
| 2025-09-12 | Eingeleitet | B. Riley Securities | Buy |
| 2024-08-06 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-04-12 | Eingeleitet | BTIG Research | Buy |
| 2024-01-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2021-11-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-09-15 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-08-25 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2021-08-24 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-10-14 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-07 | Eingeleitet | JP Morgan | Overweight |
| 2020-06-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-05-13 | Eingeleitet | Cowen | Outperform |
| 2020-01-08 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-06 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2019-10-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-29 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-06-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-05-11 | Bestätigt | Needham | Buy |
| 2016-12-21 | Eingeleitet | Needham | Buy |
| 2016-11-03 | Eingeleitet | Piper Jaffray | Overweight |
| 2016-10-12 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2016-08-03 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2016-06-20 | Eingeleitet | Guggenheim | Buy |
| 2016-06-20 | Bestätigt | Leerink Partners | Outperform |
| 2016-05-12 | Eingeleitet | Leerink Partners | Outperform |
| 2016-05-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2015-02-03 | Hochstufung | Robert W. Baird | Underperform → Neutral |
Alle ansehen
Theravance Biopharma Inc Aktie (TBPH) Neueste Nachrichten
How Theravance Biopharma Inc. (0TB) stock reacts to fiscal policiesBond Market & Long-Term Safe Investment Plans - Newser
Why Theravance Biopharma Inc. (0TB) stock attracts HNW investorsJuly 2025 Price Swings & Advanced Technical Analysis Signals - Newser
Is Theravance Biopharma Inc. stock ready for breakoutEarnings Performance Report & Free Real-Time Market Sentiment Alerts - Newser
Oppenheimer Initiates Coverage of Theravance Biopharma (TBPH) with Outperform Recommendation - Nasdaq
VP Farnum Files To Sell 31,067 Of Theravance Biopharma Inc [TBPH] - TradingView
Oppenheimer Initiates Coverage on TBPH with Outperform Rating | - GuruFocus
Oppenheimer Initiates Theravance Biopharma at Outperform With $27 Price Target - marketscreener.com
Oppenheimer initiates Theravance Biopharma stock with Outperform rating - Investing.com
Oppenheimer initiates Theravance Biopharma stock with Outperform rating By Investing.com - Investing.com Canada
Market Trends: Will Theravance Biopharma Inc stock maintain momentum in 2025July 2025 Spike Watch & Consistent Return Investment Signals - BỘ NỘI VỤ
Why analysts recommend Theravance Biopharma Inc. (0TB) stockWeekly Profit Report & Growth Focused Investment Plans - Newser
Will Theravance Biopharma Inc. stock maintain momentum in 20252025 AllTime Highs & Accurate Trade Setup Notifications - Newser
Dir Broshy Sells 29,501 ($590K) Of Theravance Biopharma Inc [TBPH] - TradingView
Trading Systems Reacting to (TBPH) Volatility - news.stocktradersdaily.com
Theravance Biopharma stock hits 52-week high at 20.29 USD By Investing.com - Investing.com Nigeria
How Theravance Biopharma Inc. stock reacts to global recession fearsTrade Volume Report & Risk Managed Investment Signals - moha.gov.vn
Theravance Biopharma stock hits 52-week high at 20.29 USD - Investing.com
Aug Movers: Will Theravance Biopharma Inc. stock outperform Dow Jones index2025 Geopolitical Influence & Short-Term High Return Ideas - BỘ NỘI VỤ
Why Theravance Biopharma Inc. stock could outperform in 2025Weekly Risk Report & Daily Chart Pattern Signal Reports - BỘ NỘI VỤ
BTIG Maintains Theravance Biopharma (TBPH) Buy Recommendation - MSN
Dir Broshy Files To Sell 29,501 Of Theravance Biopharma Inc [TBPH] - TradingView
TBPH: BTIG Raises Price Target to $40 While Maintaining Buy Rati - GuruFocus
[Form 4] Theravance Biopharma, Inc. Insider Trading Activity - Stock Titan
CFO Sawaf Surrenders 18,627 Of Theravance Biopharma Inc [TBPH] - TradingView
TBPH insider filing: CFO tax-withholding of 18,627 shares at $17.90 - Stock Titan
VP Miller Surrenders 6,989 Of Theravance Biopharma Inc [TBPH] - TradingView
VP Farnum Surrenders 9,060 Of Theravance Biopharma Inc [TBPH] - TradingView
Theravance's Q3 Earnings Surpass Estimates, Revenues Match - MSN
CEO Winningham Surrenders 56,817 Of Theravance Biopharma Inc [TBPH] - TradingView
Can Theravance Biopharma Inc. stock beat analyst upgrades - newser.com
Why pension funds invest in Theravance Biopharma Inc. (0TB) stock2025 Growth vs Value & AI Based Buy/Sell Signal Reports - newser.com
Is Theravance Biopharma Inc. stock attractive for passive investors2025 Technical Patterns & Risk Controlled Swing Alerts - newser.com
Theravance Biopharma (TBPH) is a Top-Ranked Growth Stock: Should You Buy? - MSN
Why Theravance Biopharma Inc. stock is rated strong buy2025 Fundamental Recap & Accurate Trade Setup Notifications - newser.com
Theravance Biopharma to host virtual KOL event on ampreloxetine study By Investing.com - Investing.com Nigeria
Theravance Biopharma to host virtual KOL event on ampreloxetine study - Investing.com
Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025 - 富途牛牛
Is Theravance Biopharma Inc. (0TB) stock a fit for income portfoliosJuly 2025 Review & Technical Analysis for Trade Confirmation - newser.com
Theravance Biopharma Inc. stock trendline breakdownQuarterly Profit Report & Accurate Technical Buy Alerts - newser.com
Is Theravance Biopharma Inc. stock cheap at current valuation2025 Volume Leaders & Weekly Return Optimization Alerts - newser.com
Finanzdaten der Theravance Biopharma Inc-Aktie (TBPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.82%
1.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):